Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eupatilin is a naturally occurring flavonoid (trimethoxyflavone) isolated from various Artemisia species and other plants. It exhibits anti-inflammatory, anti-ulcer, and antineoplastic activities. Mechanistically, eupatilin acts as an inhibitor of arachidonate 5-lipoxygenase (EC 1.13.11.34), thereby reducing leukotriene synthesis and inflammation[2][8]. It also suppresses pro-inflammatory cytokines (such as IL‑1β, TNF‑α, IL‑6, IL‑8) and inhibits the PI3K/NF‑κB signaling pathway in gastric epithelial cells infected with Helicobacter pylori[7][8]. Eupatilin has been studied for its protective effects against gastrointestinal lesions and bleeding—especially in the context of NSAID or aspirin use—and for its potential anticancer properties through induction of apoptosis in cancer cells[4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eupatilin.